Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enhanced EudraVigilance System Goes Live, EMA Updates Info For Users

Executive Summary

After months of preparations, the European Medicines Agency’s improved pharmacovigilance database has gone live on schedule.

You may also be interested in...



Pharma Disappointed By New Extension Of EU Signal Detection Pilot

A further extension of the EU signal detection pilot means that certain drug sponsors must keep monitoring the EudraVigilance database on a continuous basis. Industry argues there is enough evidence that this activity brings no additional value, and that current requirements should be replaced with a more proportionate approach.

EU Extends Pilot Of New Drug Safety Reporting System

Testing of the enhanced EU drug safety reporting system, EudraVigilance, is to be extended beyond February in an effort to gain more information on how stakeholders are finding the new requirements.

EMA Postpones Decision On Next Phase Of EudraVigilance To End Of 2019

The European Commission has agreed to extend the ongoing signal detection pilot involving the revamped EU pharmacovigilance database and has asked for a report on experience in the first year. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel